Drug Profile
Research programme: monoclonal antibody therapeutics - Tetragenetics/argenx /Ligand Pharmaceuticals/Eloxx Pharmaceuticals
Latest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator arGEN-X; Crystal Bioscience; Sevion Therapeutics; Tetragenetics
- Developer argenx; Eloxx Pharmaceuticals; Ligand Pharmaceuticals; Tetragenetics
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants; Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 13 Sep 2021 Tetragenetics has been acquired by Abcellera
- 28 Jan 2020 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 23 Dec 2015 Tetragenetics, arGEN-X, Crystal Bioscience and Sevion Therapeutics enter into a collaboration agreement to discover and develop monoclonal antibodies for autoimmune disorders in USA .